Neurocrine Biosciences, Inc.

477 articles with Neurocrine Biosciences, Inc.

• 

  Voyager Therapeutics CEO and CMO Resign as Company Undergoes Strategic Shift

  5/20/2021

  Shares of Voyager Therapeutics fell in aftermarket trading after its CEO and CMO announced plans to depart the company following clinical setbacks with a Parkinson’s disease program.

• Neurocrine Biosciences to Present at the 2021 RBC Global Healthcare Conference

  5/11/2021

  Neurocrine Biosciences, Inc. will present at the 2021 RBC Capital Markets Healthcare Conference at 10:55 a.m. Eastern Time on Tuesday May 18, 2021.

• Neurocrine Biosciences Reports First Quarter 2021 Financial Results

  5/5/2021

  Initiated Pediatric Phase III Registrational Program of Crinecerfont for the Treatment of Classic Congenital Adrenal Hyperplasia

• Neurocrine Biosciences to Present at the Bank of America 2021 Healthcare Conference

  5/4/2021

  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America 2021 Healthcare Conference at 11:00 a.m. Eastern Time on Tuesday May 11, 2021. Kevin Gorman, Chief Executive Officer, will present at the conference.

• Neurocrine Biosciences Supports Mental Health Month and Tardive Dyskinesia Awareness Week

  5/3/2021

  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its support of Mental Health Month and commitment to raising awareness of and supporting people living with tardive dyskinesia (TD)

• Sentia Medical Sciences and Neurocrine Biosciences Enter into Strategic Collaboration to Discover Novel CRF Peptides

  4/26/2021

  Sentia Medical Sciences Inc. today announced that they have entered into a research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) aimed at discovering novel, long-acting corticotropin-releasing factor (CRF) receptor antagonist peptide therapeutics.

• Neurocrine Biosciences Announces Appointment of Johanna Mercier to Board of Directors

  4/16/2021

  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Johanna Mercier to its Board of Directors

• Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2021 Financial Results

  4/14/2021

  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report first quarter 2021 financial results after the Nasdaq market closes on Wednesday, May 5, 2021 .

• Neurocrine Biosciences to Present Data from its Neurology Portfolio at the American Academy of Neurology's 73rd 2021 Virtual Meeting

  4/8/2021

  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data from its movement disorders and epilepsy programs at the American Academy of Neurology's (AAN) 73rd Annual Meeting being held virtually from April 17–22, 2021.

• Neurocrine Biosciences to Present at Stifel 3rd Annual CNS Day

  3/25/2021

  - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 3 rd Annual CNS Day at 12:30 p.m. Eastern Time on Thursday Apr. 1, 2021. Eiry Roberts, Chief Medical Officer, and Kyle Gano , Chief Business Development and Strategy Officer, will present at the conference.

• Neurocrine Biosciences to Present New Data Analyses for Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2021

  3/20/2021

  Neurocrine Biosciences, Inc. announced that it will present additional positive data from its Phase II CAHlibrate study of crinecerfont, an investigational, oral, non-steroidal corticotropin-releasing factor type 1 receptor antagonist for the potential treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, at ENDO 2021, the Endocrine Society's annual meeting, on March 20–23, 2021.

• Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference

  3/9/2021

  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Oppenheimer 31st Annual Healthcare Conference at 4:30 p.m. Eastern Time on Tuesday Mar. 16, 2021.

• Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)

  3/2/2021

  - Negative Outcome on Primary Endpoint Measured by the Change from Baseline on the Positive and Negative Syndrome Scale/Negative Symptom Factor Score (PANSS NSFS) - Positive Outcome on Cognitive Assessment Secondary Endpoints Support Potential Further Clinical Development of Luvadaxistat - No New Safety Signals Compared to Previous Trials of Luvadaxistat

• Neurocrine Biosciences to Present at the Cowen 41st Annual Health Care Conference

  2/23/2021

  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Cowen 41st Annual Health Care Conference at 1:30 p.m. Eastern Time on Tuesday Mar. 2, 2021. Kevin Gorman, Chief Executive Officer, will present at the conference.

• Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results

  2/4/2021

  Total Annual Revenues in 2020 Grew 33% to Over $1 Billion INGREZZA® (valbenazine) Full Year 2020 Net Product Sales and TRx Both Grew 32% to $993 Million and Approximately 175,700 TRx, Respectively Mitsubishi Tanabe Pharma Corporation (MTPC) Reports Successful Top-Line Results for Asia-Based J-KINECT Phase III Study to Evaluate the Efficacy and Safety of Valbenazine in Tardive Dyskinesia

• 

  Neurocrine Terminates Parkinson's Deal with Voyager Following Clinical Hold

  2/3/2021

  The two companies first partnered in 2019 to develop a gene therapy treatment for Parkinson’s disease, and other neurodegenerative disorders.

• Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial Results

  1/20/2021

  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report fourth quarter and year-end 2020 financial results after the Nasdaq market closes on Thursday, Feb. 4, 2021 . Neurocrine will then host a conference call and webcast

• Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones

  1/8/2021

  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update on its business performance, including preliminary net product and inventory adjusted sales results of INGREZZA® (valbenazine) for 2020, and key commercial and clinical development milestones for 2021.

• Neurocrine Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

  1/4/2021

  Neurocrine Biosciences, Inc. will present at the 39th Annual J.P. Morgan Healthcare Conference at 2:00 p.m. Eastern Time on Monday Jan. 11, 2021.

• Neurocrine Biosciences to Present at Upcoming Healthcare Conferences - Nov 19, 2020

  11/19/2020

  Neurocrine Biosciences, Inc. announced that Neurocrine Biosciences management will present at the following investor conferences:.